CHMP5 inhibitors belong to a specific chemical class that target the CHMP5 protein, a core component of the endosomal sorting complexes required for transport (ESCRT) machinery. This protein plays a pivotal role in cellular processes like membrane repair, exosome formation, and degradation pathways. The inhibitors are usually designed to specifically interfere with CHMP5's functional domains, thus effectively modulating its activity. Some of the most prominent methods for identifying these inhibitors include high-throughput screening, molecular docking simulations, and fluorescence-based assays. High-throughput screening can quickly assess the ability of thousands of compounds to inhibit CHMP5 activity, providing an initial pool of candidates for further research. Molecular docking simulations offer a computational approach, predicting how potential inhibitors can fit into CHMP5's active sites. Meanwhile, fluorescence-based assays can provide real-time insights into the binding affinities and kinetics, acting as a crucial validation step.
Chemical optimization often follows the initial identification of potential CHMP5 inhibitors. Structure-activity relationship (SAR) studies are critical in this stage, providing essential data that guides chemical modifications to improve potency, selectivity, and pharmacokinetic profiles. One of the common techniques used for SAR studies is X-ray crystallography, which provides a detailed view of how the inhibitor interacts with the CHMP5 protein at the molecular level. Computational methods, such as quantitative structure-activity relationship (QSAR) models, can also predict how different structural changes would affect the inhibitor's
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Inhibits the mTOR pathway, which can indirectly affect CHMP5 activity by altering autophagy processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Another PI3K inhibitor that can affect signaling pathways, thereby indirectly influencing CHMP5 activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor that can affect protein degradation processes, indirectly impacting CHMP5. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Histone deacetylase inhibitor that can affect gene expression, potentially influencing CHMP5 activity. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
Tyrosine kinase inhibitor that can affect cellular signaling, possibly altering CHMP5 function. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Another tyrosine kinase inhibitor affecting cellular signaling pathways that can involve CHMP5. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
Affects BRD4 and alters gene expression, thereby indirectly affecting CHMP5. | ||||||
MLN8237 | 1028486-01-2 | sc-394162 | 5 mg | $220.00 | ||
Aurora kinase inhibitor that interferes with cell cycle, thereby potentially affecting CHMP5. | ||||||
Zoledronic acid, anhydrous | 118072-93-8 | sc-364663 sc-364663A | 25 mg 100 mg | $90.00 $251.00 | 5 | |
Inhibits farnesyl diphosphate synthase, affecting prenylation processes which may involve CHMP5. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Inhibits Src family kinases, thereby affecting signaling pathways that can involve CHMP5. |